Alvotech SA and Advanz Pharma have received marketing authorisations from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Gobivaz®, a biosimilar to Simponi® (golimumab). The approvals cover all four presentations of Gobivaz®-50 mg/0.5 mL and 100 mg/mL in both pre-filled syringe and autoinjector formats-for the treatment of several immune-mediated diseases, including rheumatoid arthritis, psoriatic arthritis, axial spondylarthritis, ulcerative colitis in adults, and juvenile idiopathic arthritis. Additionally, the European Medicines Agency's Committee for Medicinal Products for Human Use $(CHMP)$ has issued a positive opinion recommending approval of Gobivaz® across the European Economic Area. Under their partnership, Alvotech is responsible for development and supply, while Advanz Pharma manages registration and commercialisation in Europe and the UK.